Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world

Background: Previous data, mostly from clinical trials, reported that HER2-low status is associated with low pathological complete response (pCR), and favourable prognosis. Since these findings suggest the existence of an additional breast cancer subtype, we questioned if the predictive/prognostic v...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Cosimo, Serena, La Rocca, Eliana, Ljevar, Silva, De Santis, Maria Carmen, Bini, Marta, Cappelletti, Vera, Valenti, Marta, Baili, Paolo, de Braud, Filippo G., Folli, Secondo, Scaperrotta, Gianfranco, Volpi, Chiara, Vingiani, Andrea, Vernieri, Claudio, Verderio, Paolo, Miceli, Rosalba, Pruneri, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549400/
https://www.ncbi.nlm.nih.gov/pubmed/36225259
http://dx.doi.org/10.3389/fmolb.2022.996434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549400/
https://www.ncbi.nlm.nih.gov/pubmed/36225259
http://dx.doi.org/10.3389/fmolb.2022.996434

Ejemplares similares